Adverse reactions of L-asparaginase.
Adverse reactions to L-asparaginase in children undergoing induction therapy for acute lymphocytic leukemia have previously been described and have been noted to include hypersensitivity reactions, pancreatitis, hepatic dysfunction, nephrotoxicity, and central nervous system dysfunction. Recently, however, newly described abnormalities in hematological and hemostatic function have resulted in intracranial hemorrhage and thrombosis of the extremities, immune hemolytic anemia and abnormal collagen stimulated platelet aggregation. The coagulopathy appears to be a result of a combination of events related to decreased synthesis of fibrinogen, antithrombin III and plasminogen. Implications for future modifications of L-asparaginase therapy are further discussed.
D000743:Anemia, Hemolytic / Q000139:chemically induced; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D010195:Pancreatitis / Q000139:chemically induced; D010974:Platelet Aggregation / Q000187:drug effects
D001215:Asparaginase